No Data
Little Excitement Around China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): Currently, the company has no equity cooperation with Thalys Medical Technology Group Corporation.
On December 11, Gelonghui reported that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated on the investor interaction platform that the company currently has no equity cooperation with Thalys Medical Technology Group Corporation.
China Resources Sanjiu Medical & Pharmaceutical Negotiates Inclusion of Two Products in Medical Insurance Catalog
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): The company's products and those of its subsidiaries have been included in the national medical insurance catalog for the first time through negotiations.
According to the announcement by China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) on November 28, the company's pharmaceutical products Wenjing Tang granules and the pharmaceutical injection Cefuroxime Sodium of its wholly-owned subsidiary Zhejiang China Resources Jiuzhong Medical Pharmaceutical Co., Ltd. were included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)" for the first time through negotiation, based on the notice issued by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security on the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2024)" (referred to as the "2024 Drug List").
Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference
① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.
China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Investors Will Be Pleased With Their Strong 123% Return Over the Last Three Years
